Abstract:Clinical evidence has revealed that while RAS/RAF/MEK/ERK pathway is a crucial component of melanomagenesis, other signaling pathways can also contribute to the malignant growth and development of resistance to targeted therapies. We explored the response of V600EBRAF melanoma cells derived from surgical specimens and grown in stem cell medium to vemurafenib and trametinib, drugs targeting the activity of V600EBRAF and MEK1/2, respectively. Cell growth and apoptosis were monitored by real-time imaging system, immunophenotype and cell cycle by flow cytometry, gene expression by quantitative real-time PCR, immunoblotting and enzyme-linked immunosorbent assay. The V600EBRAF melanoma cell populations were diverse. Differences in morphology, pigmentation, cell cycle profiles, and immunophenotype were observed. At the molecular level, melanoma cells differed in the phosphorylation of ERK1/2, NF-κB, and β-catenin, and expression of several relevant genes, including MITF-M, DKK1, CCND1, BRAF, CXCL8, and CTGF. Despite having different characteristics, melanoma cells responded similarly to vemurafenib and trametinib. Both drugs reduced ERK1/2 phosphorylation and percentages of cells expressing Ki-67 at high level, inhibited expression of CCND1 and induced cell cycle arrest in the Go/G1 phase. These expected cytostatic effects were accompanied by increased CD271 expression, a marker of stem-like cells. NF-κB activity was reduced by both drugs, however, not completely abolished, whereas the level of active β-catenin was increased by drugs in three out of six cell populations. Interestingly, expression of IL-8 and CTGF was significantly reduced by treatment with vemurafenib and trametinib. Simultaneous inhibition of NF-κB activity and induction of ERK1/2 phosphorylation revealed that CTGF expression depends on ERK1/2 activity but not on NF-κB activity. Both, the positive effects of treatment with vemurafenib and trametinib such as the newly identified CTGF suppression and undesired effects such as increased CD271 expression suggesting selection of melanoma stem-like cells should be considered in the development of combination treatment for melanoma patients.

RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma

Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma

Sestrin2 Contributes to BRAF Inhibitor Resistance Via Reducing Redox Vulnerability of Melanoma Cells

VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer.

Mir‐200c/bmi1 Axis and Epithelial–mesenchymal Transition Contribute to Acquired Resistance to BRAF Inhibitor Treatment

The EGF/EGFR-YAP1/TEAD2 axis-mediated BRAF inhibitor vemurafenib resistance upregulates STIM1 in melanoma

Vemurafenib Induces a Noncanonical Senescence-Associated Secretory Phenotype in Melanoma Cells Which Promotes Vemurafenib Resistance.

Transcriptomic Alterations Induced by Vemurafenib after Treatment of Melanoma: A Comprehensive Bioinformatics Analysis

The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B

The Positive Correlation Between Drug Addiction And Drug Dosage In Vemurafenib-Resistant Melanoma Cells Is Underpinned By Activation Of Erk1/2-Fra-1 Pathway

Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells

Src-dependent DBL family members drive resistance to vemurafenib in human melanoma

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

EGF/EGFR‐YAP1/TEAD2 signaling upregulates STIM1 in vemurafenib resistant melanoma cells

Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells

LKB1 loss cooperating with BRAF V600E promotes melanoma cell invasion and migration by up-regulation MMP-2 via PI3K/Akt/mTOR pathway

Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.

Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.